TrialJournal of clinical oncology : official journal of the American Society of Clinical Oncology2017

Phase I/II Trial of Labetuzumab Govitecan (Anti-CEACAM5/SN-38 Antibody-Drug Conjugate) in Patients With Refractory or Relapsing Metastatic Colorectal Cancer.

Efrat Dotan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.